BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38754311)

  • 21. PMA induces androgen receptor downregulation and cellular apoptosis in prostate cancer cells.
    Itsumi M; Shiota M; Yokomizo A; Takeuchi A; Kashiwagi E; Dejima T; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
    J Mol Endocrinol; 2014 Aug; 53(1):31-41. PubMed ID: 24780839
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer.
    Kregel S; Chen JL; Tom W; Krishnan V; Kach J; Brechka H; Fessenden TB; Isikbay M; Paner GP; Szmulewitz RZ; Vander Griend DJ
    Oncotarget; 2016 May; 7(18):26259-74. PubMed ID: 27036029
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of pyridine tetrahydroisoquinoline thiohydantoin derivatives with low blood-brain barrier penetration as the androgen receptor antagonists.
    Xu X; Du Q; Meng Y; Li Z; Wu H; Li Y; Zhao Z; Ge R; Lu X; Xue S; Chen X; Yang Y; Wang J; Bian J
    Eur J Med Chem; 2020 Apr; 192():112196. PubMed ID: 32169785
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer.
    Saito Y; Mizokami A; Tsurimoto H; Izumi K; Goto M; Nakagawa-Goto K
    Eur J Med Chem; 2018 Sep; 157():1143-1152. PubMed ID: 30189396
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Collateral resistance to taxanes in enzalutamide-resistant prostate cancer through aberrant androgen receptor and its variants.
    Shiota M; Dejima T; Yamamoto Y; Takeuchi A; Imada K; Kashiwagi E; Inokuchi J; Tatsugami K; Kajioka S; Uchiumi T; Eto M
    Cancer Sci; 2018 Oct; 109(10):3224-3234. PubMed ID: 30051622
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer.
    Asangani IA; Wilder-Romans K; Dommeti VL; Krishnamurthy PM; Apel IJ; Escara-Wilke J; Plymate SR; Navone NM; Wang S; Feng FY; Chinnaiyan AM
    Mol Cancer Res; 2016 Apr; 14(4):324-31. PubMed ID: 26792867
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-Steroidal Androgen Receptor Antagonists and Prostate Cancer: A Survey on Chemical Structures Binding this Fast-Mutating Target.
    Ferroni C; Varchi G
    Curr Med Chem; 2019; 26(33):6053-6073. PubMed ID: 30209993
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oxidative stress in peroxisomes induced by androgen receptor inhibition through peroxisome proliferator-activated receptor promotes enzalutamide resistance in prostate cancer.
    Shiota M; Ushijima M; Tsukahara S; Nagakawa S; Okada T; Tanegashima T; Kobayashi S; Matsumoto T; Eto M
    Free Radic Biol Med; 2024 Aug; 221():81-88. PubMed ID: 38762061
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant AR
    Wu Z; Wang K; Yang Z; Pascal LE; Nelson JB; Takubo K; Wipf P; Wang Z
    Prostate; 2020 Mar; 80(4):319-328. PubMed ID: 31868960
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, Synthesis and Evaluation of Novel Substituted (5-methyl-1H-pyrazol-3-yl)- 1,3,4-oxadiazole as Potent Androgen Receptor Antagonist.
    Andavar S; Vaithilingam M; Selvaraj D; Kumaran AA; Devanathan K
    Anticancer Agents Med Chem; 2020; 20(1):84-93. PubMed ID: 31755396
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer.
    Liu C; Lou W; Zhu Y; Nadiminty N; Schwartz CT; Evans CP; Gao AC
    Clin Cancer Res; 2014 Jun; 20(12):3198-3210. PubMed ID: 24740322
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Continued androgen signalling inhibition improves cabazitaxel efficacy in prostate cancer.
    Mout L; van Royen ME; de Ridder C; Stuurman D; van de Geer WS; Marques R; Buck SAJ; French PJ; van de Werken HJG; Mathijssen RHJ; de Wit R; Lolkema MP; van Weerden WM
    EBioMedicine; 2021 Nov; 73():103681. PubMed ID: 34749299
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting persistent androgen receptor signaling in castration-resistant prostate cancer.
    Graham L; Schweizer MT
    Med Oncol; 2016 May; 33(5):44. PubMed ID: 27042852
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preclinical pharmacology of FL442, a novel nonsteroidal androgen receptor modulator.
    Poutiainen PK; Huhtala T; Jääskeläinen T; Petsalo A; Küblbeck J; Kaikkonen S; Palvimo JJ; Raunio H; Närvänen A; Peräkylä M; Juvonen RO; Honkakoski P; Laatikainen R; Pulkkinen JT
    Mol Cell Endocrinol; 2014 Apr; 387(1-2):8-18. PubMed ID: 24565895
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Androgen receptor antagonists produced by Streptomyces overcome resistance to enzalutamide.
    Imoto M; Fujimaki T; Saito S; Tashiro E
    J Antibiot (Tokyo); 2021 Oct; 74(10):706-716. PubMed ID: 34282313
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer.
    Liu C; Armstrong CM; Lou W; Lombard AP; Cucchiara V; Gu X; Yang JC; Nadiminty N; Pan CX; Evans CP; Gao AC
    Mol Cancer Ther; 2017 Aug; 16(8):1521-1530. PubMed ID: 28500234
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Isolation and characterization of castration-resistant prostate cancer LNCaP95 clones.
    Leung JK; Tam T; Wang J; Sadar MD
    Hum Cell; 2021 Jan; 34(1):211-218. PubMed ID: 32954481
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis and Biological Evaluation of Bicalutamide Analogues for the Potential Treatment of Prostate Cancer.
    Kandil SB; McGuigan C; Westwell AD
    Molecules; 2020 Dec; 26(1):. PubMed ID: 33374450
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design and synthesis of 4-benzyl-1-(2H)-phthalazinone derivatives as novel androgen receptor antagonists.
    Inoue K; Urushibara K; Kanai M; Yura K; Fujii S; Ishigami-Yuasa M; Hashimoto Y; Mori S; Kawachi E; Matsumura M; Hirano T; Kagechika H; Tanatani A
    Eur J Med Chem; 2015 Sep; 102():310-9. PubMed ID: 26295173
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and biological evaluation of arylpiperazine derivatives as potential anti-prostate cancer agents.
    Chen H; Yu YZ; Tian XM; Wang CL; Qian YN; Deng ZA; Zhang JX; Lv DJ; Zhang HB; Shen JL; Yuan M; Zhao SC
    Bioorg Med Chem; 2019 Jan; 27(1):133-143. PubMed ID: 30482547
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.